Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04375033 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
A Phase 4 study of Opioid Use Disorder, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 952
- Enrollment target
- 20
- Study locations
NCT04375033 is a Phase 4 study of Opioid Use Disorder that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 952 participants, below the 4,653-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT04375033, a Phase 4 study of Opioid Use Disorder, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 952 participants
- Enrollment target
- 20
- Study locations
Study Summary
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 4-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.
Conditions Studied
Interventions
- DRUG Sublingual buprenorphine with naloxone
- DRUG Injectable subcutaneous buprenorphine
Study Locations (20)
California
- VA Long Beach Healthcare System, Long Beach, CA - Long Beach
- VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto
- San Francisco VA Medical Center, San Francisco, CA - San Francisco
Connecticut
- CERC (VISN1, West Haven, CT) - West Haven
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
Florida
- Bay Pines VA Healthcare System, Pay Pines, FL - Bay Pines
- North Florida/South Georgia Veterans Health System, Gainesville, FL - Gainesville
Ohio
- Louis Stokes VA Medical Center, Cleveland, OH - Cleveland
- Dayton VA Medical Center, Dayton, OH - Dayton
Pennsylvania
- Philadelphia MultiService Center, Philadelphia, PA - Philadelphia
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA - Pittsburgh
Alabama
- Tuscaloosa VA Medical Center, Tuscaloosa, AL - Tuscaloosa
Arizona
- Phoenix VA Health Care System, Phoenix, AZ - Phoenix
Delaware
- Wilmington VA Medical Center, Wilmington, DE - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 952 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2029-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04375033
The ClinicalTrials.gov registry entry for NCT04375033 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 952 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,653-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (80% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Sublingual buprenorphine with naloxone is the first listed.
NCT04375033 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT04375033 about?
NCT04375033 is a clinical study titled "A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder". VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation...
What is the current status of trial NCT04375033?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 952 participants. The study started on 2020-11-03. Estimated completion is 2029-05-31.
What conditions does trial NCT04375033 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT04375033?
The interventions under investigation include: Sublingual buprenorphine with naloxone (DRUG), Injectable subcutaneous buprenorphine (DRUG).
Who is sponsoring clinical trial NCT04375033?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04375033 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
Assessing Optimal XRB Initiation Points in Jail
RECRUITING · Phase 4
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
RECRUITING · Phase 4
-
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.